Omeros Co. (NASDAQ:OMER) Given Average Recommendation of “Moderate Buy” by Analysts

Omeros Co. (NASDAQ:OMER) has been assigned an average rating of “Moderate Buy” from the five analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $22.50.

Several equities analysts recently issued reports on OMER shares. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Thursday, February 20th.

Omeros Price Performance

NASDAQ OMER opened at $8.42 on Friday. Omeros has a 1 year low of $2.61 and a 1 year high of $13.60. The stock has a market capitalization of $487.94 million, a PE ratio of -3.65 and a beta of 2.03. The business’s 50-day moving average is $8.80 and its 200 day moving average is $7.15.

Institutional Investors Weigh In On Omeros

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Truvestments Capital LLC boosted its position in shares of Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 1,972 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Omeros in the fourth quarter worth $46,000. BNP Paribas Financial Markets increased its holdings in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 7,016 shares in the last quarter. Finally, Picton Mahoney Asset Management raised its position in shares of Omeros by 692.5% in the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 4,404 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.